CN1863789B - 取代的异喹啉酮 - Google Patents

取代的异喹啉酮 Download PDF

Info

Publication number
CN1863789B
CN1863789B CN2004800289444A CN200480028944A CN1863789B CN 1863789 B CN1863789 B CN 1863789B CN 2004800289444 A CN2004800289444 A CN 2004800289444A CN 200480028944 A CN200480028944 A CN 200480028944A CN 1863789 B CN1863789 B CN 1863789B
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
fluoro
alkoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800289444A
Other languages
English (en)
Chinese (zh)
Other versions
CN1863789A (zh
Inventor
罗伯特·M·斯卡伯勒
基姆·A·凯恩-马吉雷
查尔斯·K·马洛
马克·S·史密斯
张晓明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN1863789A publication Critical patent/CN1863789A/zh
Application granted granted Critical
Publication of CN1863789B publication Critical patent/CN1863789B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2004800289444A 2003-10-03 2004-09-29 取代的异喹啉酮 Expired - Fee Related CN1863789B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
US60/508,402 2003-10-03
PCT/US2004/032104 WO2005035520A1 (en) 2003-10-03 2004-09-29 Substituted isoquinolinones

Publications (2)

Publication Number Publication Date
CN1863789A CN1863789A (zh) 2006-11-15
CN1863789B true CN1863789B (zh) 2010-06-09

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800289444A Expired - Fee Related CN1863789B (zh) 2003-10-03 2004-09-29 取代的异喹啉酮

Country Status (10)

Country Link
US (1) US7294635B2 (OSRAM)
EP (1) EP1667989A4 (OSRAM)
JP (1) JP4879745B2 (OSRAM)
KR (1) KR20060113699A (OSRAM)
CN (1) CN1863789B (OSRAM)
AU (1) AU2004279809B2 (OSRAM)
CA (1) CA2539882A1 (OSRAM)
IL (1) IL174445A (OSRAM)
MX (1) MXPA06003625A (OSRAM)
WO (1) WO2005035520A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812429A4 (en) * 2004-09-29 2010-07-21 Portola Pharm Inc SUBSTITUTED 2H-1,3-BENZOXAZIN-4 (3H) -ONE
WO2007008140A1 (en) * 2005-07-13 2007-01-18 Astrazeneca Ab New pyridine analogues
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
WO2008004942A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New pyridine analogues
CN101506193A (zh) * 2006-07-04 2009-08-12 阿斯利康(瑞典)有限公司 新吡啶类似物
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
WO2008133155A1 (ja) 2007-04-19 2008-11-06 Astellas Pharma Inc. 二環式ヘテロ環化合物
CN101686959B (zh) 2007-05-02 2014-05-07 波托拉医药品公司 作为血小板adp受体抑制剂的化合物的组合疗法
PE20081892A1 (es) * 2007-07-13 2009-02-21 Astrazeneca Ab Nuevos analogos de amino-piridina como agentes antitromboticos
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
ES2718175T3 (es) * 2014-12-02 2019-06-28 Lilly Co Eli Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
PT3578547T (pt) 2015-02-16 2021-06-22 The Provost Fellows Found Scholars And Other Members Of Board Of College Of Holy And Undivided Trini Sulfonilureias e compostos relacionados e uso dos mesmos
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
UY37847A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
MX2020004423A (es) 2017-11-09 2020-08-06 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida.
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5475025A (en) * 1993-01-27 1995-12-12 The Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US20020077486A1 (en) * 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板ａｄｐ受容体阻害剤
ATE309999T1 (de) * 2000-02-04 2005-12-15 Portola Pharm Inc Blutplättchen-adp-rezeptor-inhibitoren

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5475025A (en) * 1993-01-27 1995-12-12 The Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US20020077486A1 (en) * 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors

Also Published As

Publication number Publication date
US7294635B2 (en) 2007-11-13
EP1667989A1 (en) 2006-06-14
JP2007507519A (ja) 2007-03-29
JP4879745B2 (ja) 2012-02-22
MXPA06003625A (es) 2006-08-11
WO2005035520A1 (en) 2005-04-21
AU2004279809B2 (en) 2010-07-15
IL174445A (en) 2012-02-29
US20050113399A1 (en) 2005-05-26
AU2004279809A1 (en) 2005-04-21
EP1667989A4 (en) 2008-08-20
KR20060113699A (ko) 2006-11-02
CN1863789A (zh) 2006-11-15
CA2539882A1 (en) 2005-04-21
IL174445A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
CN1863789B (zh) 取代的异喹啉酮
CN1863798B (zh) 2,4-二氧代-3-喹唑啉基芳基磺酰基脲
KR101892987B1 (ko) 신규한 소염제
US7205296B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
KR101803259B1 (ko) 신규한 소염제
US9540360B2 (en) Sulfonamide compounds having TRPM8 antagonistic activity
CN102159208B (zh) 6-1h-咪唑-1-基喹唑啉和喹啉衍生物、新的mao抑制剂和咪唑啉受体配体
US20090286775A1 (en) Bicyclic Derivatives as P38 Kinase Inhibitors
KR20030031483A (ko) 포스포디에스테라제 억제제로서 유용한 치환된피롤로피리디논 유도체
JP2002519348A (ja) ５−ｈｔ１ｆアゴニスト
CA2640665A1 (en) Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives
CN105722835A (zh) 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
JP2000517301A (ja) テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
WO2006057270A1 (ja) 含窒素３環化合物
EP2896613B1 (en) Sulfonamide compound
JP2007511570A (ja) 不適切なａｌｋ５に関連する疾患を治療するための１−アミノ−イソキノリン誘導体
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
KR20000016715A (ko) 치환된 벤즈아미드 유도체 및 항경련제로서의그의 용도ㅔ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100609

Termination date: 20120929